Presence, number of GI symptoms linked to greater impairment in internalizing behaviors, sleep, communication, sensory processing, and repetitive behaviors
Significant mean change in body weight from baseline to week 72 seen with various dosages of orforglipron compared with placebo among adults with obesity
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy